ArticleMicroorganisms2020
Anti-Mycobacterial Antibiotic Therapy Induces Remission in Active Paediatric Crohn's Disease.
Article in Microorganisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Review
- Influence of landscape on the distribution of inflammatory bowel disease in England and Wales.BMC public health · 2026Article
- Crohn's Disease in Malaysia: Could Application of the Precautionary Principle Reduce Future Incidence?Microorganisms · 2026Review
- Viewpoint: The Use of Antimycobacterial (Anti-MAP) Therapies in the Treatment of Active Luminal Crohn's Disease.JGH open : an open access journal of gastroenterology and hepatology · 2025Review
- RNA-sequencing studies suggest that microRNAs and alternative splicing of pre-mRNAs modulate immune and inflammatory responses in Holstein cattle infected withFrontiers in immunology · 2025Review
- Antibiotic Therapy for Active Crohn's Disease Targeting Pathogens: An Overview and Update.Antibiotics (Basel, Switzerland) · 2024Review
- Advancing therapeutic frontiers: a pipeline of novel drugs for luminal and perianal Crohn's disease management.Therapeutic advances in gastroenterology · 2024Review
- Long Non-Coding RNAs and Their "Discrete" Contribution to IBD and Johne's Disease-What Stands out in the Current Picture? A Comprehensive Review.International journal of molecular sciences · 2023Review
- The evidence forTranslational cancer research · 2023Review
- Review
- Quantitative Risk Assessment of Exposure toFoods (Basel, Switzerland) · 2022Article
- Bacterial Species Associated With Human Inflammatory Bowel Disease and Their Pathogenic Mechanisms.Frontiers in microbiology · 2022Review
- Putting Crohn's on the MAP: Five Common Questions on the Contribution of Mycobacterium avium subspecies paratuberculosis to the Pathophysiology of Crohn's Disease.Digestive diseases and sciences · 2021Review
- What is the evidence that mycobacteria are associated with the pathogenesis of Sjogren's syndrome?Journal of translational autoimmunity · 2021Review
- Crohn's strictures open with anti-mycobacterial antibiotic therapy: A retrospective review.World journal of gastrointestinal endoscopy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease is increasing in incidence and prevalence in younger people and is of a particularly aggressive nature. One emerging treatment targets
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.